GlaxoSmithKline (GSK) and South Korean pharmaceutical company SK Bioscience have started a phase 3 trial of their Covid-19 vaccine combination, the Press Association reported.
The vaccine will be tested in comparison with the Oxford / Astra Zeneca vaccine.
GSK said on Tuesday that the breakthrough followed “positive” interim results from the Phase 1 and 2 studies.
They are now aiming for global supply via the installation of Covax in the first half of 2022. This is subject to data and regulatory reviews.
The latest figures show that around 88% of the UK population over 16 has received at least one dose of the vaccine.
Thomas Breuer, head of global health at GSK, said: “Although many countries have made good progress on immunization, there remains a need for accessible and affordable Covid-19 vaccines to ensure equitable access and protect people around the world.
“We are delighted to contribute with GSK’s Pandemic Adjuvant and to work with SK to deliver the vaccine on a large scale via Covax if approved.”
The trial will use the vaccine against the Oxford / Astra Zeneca vaccine to assess its safety and immunogenicity.
GSK said this study will be one of the first advanced global trials to compare with two different vaccine candidates.
SK Bioscience CEO Jaeyong Ahn said, “We are grateful that we were able to move to the Phase 3 study with the unprecedented support of global initiatives including GSK, the Coalition for Epidemic Preparedness Initiative and the Bill & Melinda Gates Foundation.
“In taking this important step to overcome the global pandemic situation, SK and GSK will pool their technical expertise for the development of an adjuvanted protein vaccine candidate, GBP510. ”
More about this article: Read More
This notice was published: 2021-09-01 06:00:00